Evidence map›Paper›PMID 36820001›Full record

ArticleFrontiers in immunology2022

How COVID-19 and other pathological conditions and medical treatments activate our intravascular innate immune system.

Bo Nilsson, Oskar Eriksson, Karin Fromell, Barbro Persson, Kristina N Ekdahl

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bo NilssonDepartment of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden.
Oskar ErikssonDepartment of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden.
Karin FromellDepartment of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden.
Barbro PerssonDepartment of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden.
Kristina N EkdahlDepartment of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden.
Uppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 has been shown to have a multifaceted impact on the immune system. In a recently published article in Front Immunol, we show that the intravascular innate immune system (IIIS) is strongly activated in severe COVID-19 with ARDS and appears to be one of the causes leading to severe COVID-19. In this article, we describe the IIIS and its physiological function, but also the strong pro-inflammatory effects that are observed in COVID-19 and in various other pathological conditions and treatments such as during ischemia reperfusion injury and in treatments where biomaterials come in direct contact with blood in, e.g., extracorporeal and intravasal treatments. In the present article, we describe how the IIIS, a complex network of plasma proteins and blood cells, constitute the acute innate immune response of the blood and discuss the effects that the IIIS induces in pathological disorders and treatments in modern medicine.

Indexed as

COVID-19HumansImmune SystemImmunity, Innateblood cascade systemscross talkintravascular innate immune systemleukocytesplatelets

Identifiers

PMID36820001
PMCPMC9938760
OpenAlexW4319224352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.